Evidence map›Paper›PMID 30978988›Full record

ReviewPolymers2019

Cyclodextrins and Cyclodextrin Derivatives as Green Char Promoters in Flame Retardants Formulations for Polymeric Materials. A Review.

Maria Paola Luda, Marco Zanetti

Abstract readReview
In one paragraph

Review in Polymers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maria Paola LudaDipartimento di Chimica, Università di Torino, Via P. Giuria 7, 10125 Torino, Italy. mariapaola.luda@unito.it.ORCID 0000-0001-7382-8931
Marco ZanettiDipartimento di Chimica, Università di Torino, Via P. Giuria 7, 10125 Torino, Italy. marco.zanetti@unito.it.ORCID 0000-0001-7074-9859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymers are intrinsically flammable materials; hence, fire retardance (FR) is required in their most common applications (i.e., electronic and construction, to mention some). Recently, it has been reported that cyclodextrin (CD) and cyclodextrin derivatives are beginning to be introduced into Intumescent Fire Retardant (IFR) formulations in place of pentaerythritol, which is used in IFRs that are currently on the market. Since IFRs are of less environmental concern than their hazardous halogen containing counterparts, the use of natural origin compounds in IFRs provides a way to comply with green chemistry issues. BCD and BCD derivatives presence in IFR mixtures promotes a higher yield of blowing gases and char when polymeric materials undergo combustion. Both processes play important roles in intumescence. The key rule to obtain in insulating compact char is the good dispersion of the nanoparticles in the matrix, which can be achieved by functionalizing nanoparticles with BCD derivatives. Moreover, CD derivatives are attractive because of their nanosized structure and their ability to form inclusion complexes with many compounds used as FR components, reducing their release to the environment during their shelf life of FR items. Often, fire retardance performed by BCD and BCD derivatives accompanies other relevant properties, such as improved mechanical resistance, washability resistance, self healing ability, thermal conductivity, etc. The application of CD fire retardant additives in many polymers, such as poly(lactic acid), poly(propylene), poly(vinyl acetate), poly(methyl methacrylate), linear low density poly(ethylene), polyamides, and polyesters are comprehensively reviewed here.

Indexed as

charcyclodextrininclusion complexnanospongephosphorous fire retardant

Identifiers

PMID30978988
PMCPMC6523419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.